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While cell-based screens have considerable power in
identifying new chemical probes of biological sys-
tems and leads for new drugs, a major challenge to
the utility of such compounds is in connecting
phenotype with a cellular target. Here, we present a
systematic study to elucidate the mechanism of
action of uncharacterized inhibitors of the growth of
Escherichia coli through careful analyses of interac-
tions with compounds of known biological activity.
We studied growth inhibition with a collection of
200 antibacterial compounds when systematically
combined with a panel of 14 known antibiotics of
diverse mechanism and chemical class. Our work
revealed a high frequency of synergistic chemical-
chemical interactions where the interaction profiles
were unique to the various compound pairs. Thus,
thework revealed that chemical-chemical interaction
data provides a fingerprint of biological activity and
testable hypotheses regarding the mechanism of
action of the novel bioactive molecules. In the study
reported here, we determined the mode of action of
an inhibitor of folate biosynthesis and a DNA gyrase
inhibitor. Moreover, we identified eight membrane-
active compounds, found to be promiscuously
synergistic with known bioactives.
INTRODUCTION
Phenotype-based small molecule screening has emerged as a
dominant approach for the discovery of new probes of complex
biology and of leads for new drugs. While cell-based screens
have considerable power in the discovery of new chemical
matter with biological activity, the major challenge to the utility
of such molecules is an understanding of mechanism of action.
Nowhere is the discovery of new bioactive chemical matter
more important than in antibacterial research. With existing anti-
biotics directed at a small number of targets, principally cell wall,
DNA and protein biosynthesis, multidrug resistance among
bacterial pathogens is thought to be due in large part to the852 Chemistry & Biology 17, 852–862, August 27, 2010 ª2010 Elsevilimited repertoire of antibacterial chemical matter that eradicate
bacteria using a narrow range of mechanisms. Indeed, multidrug
resistance in bacteria continues to be a health-care burden in
both hospital and community settings where strains of some
pathogens, e.g., Pseudomonas aeruginosa, Staphylococcus
aureus, and Mycobacterium tuberculosis, resist the action of
every antibiotic in use (Boucher et al., 2009).
In addition to the well-recognized value of small bioactive
molecules as leads for new drugs, there is an emerging demand
for new chemical perturbants of biological complexity (Peterson,
2008). While genetic perturbation, either by mutagenesis or
targeted gene deletion, is the conventional route to probe cellular
function it has drawbacks (Alaimo et al., 2001; Stockwell, 2000).
Genetic inactivation is permanent, frequently ‘‘all or none’’ in
scope and for genes that are essential is fraught with the diffi-
culty of creating conditional alleles. Further, the introduction of
multiple mutations in the same cell is tedious in even the most
tractable systems.
A considerable obstacle to the use of small molecules as
probes of biological systems is the limited availability of highly
characterized probes. While cell-based screens have consider-
able power in identifying new chemical perturbants, a major
challenge to the utility of such probes is in understanding mech-
anism of action (Burdine and Kodadek, 2004). There is simply a
paucity of systematic methods to reveal the cellular target or
mechanism of action of phenotype-altering small molecules.
Classically, protein targets have been identified biochemically
using labeled or immobilized molecules. Among the most
exciting advances in systematic approaches has been the devel-
opment of a competitive growth assay using a pool of barcoded
genome-wide heterozygous yeast strains to identify mutants
that fail to grow in the presence of growth inhibitory drugs (Baetz
et al., 2004; Giaever et al., 1999; Lum et al., 2004b; Parsons et al.,
2004). More recently, with the explosion of genomic sequence
information and associated tools, efforts to identify cellular
targets have turned to genome-scale clone sets for the system-
atic identification of protein targets of small molecules of interest
(Hillenmeyer et al., 2008; Pathania et al., 2009). Such approaches
have largely been limited to model microbes (Baetz et al., 2004;
Giaever et al., 1999; Lum et al., 2004a; Parsons et al., 2004), and
in a recent application, to the pathogen Staphylococcus aureus
(Donald et al., 2009). While the aforementioned tools have
proved their utility in characterizing both existing and novel
bioactives, their biggest drawback lies in the requirement forer Ltd All rights reserved
Figure 1. Chemical-Chemical Interaction Profiling to Characterize
Novel Growth Inhibitory Compounds Derived from Small Molecule
Screening
Summary of the approach to understand mechanism(s) of action of a novel
active chemical matter. Synergies uncovered through combination studies,
where priority actives are systematically combined with a panel of known
bioactive compounds of diversemechanism and chemical class, provide clues
about the pathways and targets. See also Table S1.
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organisms under study, and are virtually impossible to transfer to
even closely related species, highlighting the need for system-
atic methods that are universally applicable to understanding
the mechanism of action of small molecules, independent of
the biological system of interest.
Out of recognition of the complexity and redundancy of
biological networks, chemical combinations are increasingly
touted as having special utility as both therapies and probes of
biological systems (Leha´r et al., 2008a; Zimmermann et al.,
2007). The biological impact of combinations of chemicals can
be classified as synergistic, additive, or antagonistic, depending
on whether the combined effect of the compounds is larger than,
equal to or smaller than the effects that might be predicted from
the individual drugs, respectively. The potential for efficacious
drug synergy has long led to the routine testing and use of
drug combinations, especially in antimicrobial therapies, but
largely as an afterthought to the discovery of antibiotics (Moeller-Chemistry & Biology 17, 85ing, 1983). A renaissance in interest in exploiting the power of
chemical combinations in drug discovery has been accompa-
nied by an emerging awareness of the value of simultaneous
application of two molecular probes to gain biological insight
(Leha´r et al., 2008b; Yeh and Kishony, 2007; Yeh et al., 2006).
It is nevertheless the early days in chemical combination
research and there have been no systematic applications of
chemical-chemical interaction profiling to understand the mech-
anism of action of novel bioactive molecules discovered in
high-throughput screening.
In the work described herein, we have taken a systematic
approach to elucidating themechanism of action of uncharacter-
ized inhibitors of the growth of Escherichia coli through
meticulous analyses of interactions with compounds of known
biological activity. We have examined growth inhibition of
E. coli using a collection of 200 novel antibacterial compounds
of unknown mechanism when combined with a panel of 14
known bioactive antibiotics of diverse mechanism and chemical
class. Our work revealed a surprising frequency of synergistic
chemical-chemical interactions where the interaction profiles
were unique to the various compound pairs. Thus, these studies
revealed that chemical-chemical interaction data can provide a
fingerprint of biological activity and testable hypotheses re-
garding the mechanism of action of the novel bioactive mole-
cules. We determined themode of action of two novel antibacte-
rial compounds. One molecule was found to be an inhibitor of
folate biosynthesis and the other a DNA gyrase inhibitor. Further,
the method allowed for the identification of membrane-active
compounds. These compounds showed promiscuous syner-
gistic behavior in combination with various known bioactives.
Of interest, we identified eight compounds that were capable
of depolarizing the membrane of E. coli.
RESULTS
A Screen for Growth Inhibitory Small Molecules
Our work began with a high-throughput screen to identify bioac-
tive molecules from a library of approximately 50,000 small
molecules that were growth inhibitory against E. coli strain
MC1061 (Li et al., 2004). E. coli MC1061 is an outer membrane
hyperpermeable mutant, making it hypersensitive to known anti-
biotics (Casabadan and Cohen, 1980). A subset of actives,
namely, 203 compounds (see Table S1 available online), was
selected based on structural diversity, solubility, and resupply
(Figure 1). Further prioritization based on minimum inhibitory
concentration (MIC) determination against E. coli MC1061
excluded 17 compounds with high minimum inhibitory concen-
trations (R102.4 mg/ml) (Figure 1). These remaining 186 mole-
cules were further subjected to combination profiling with known
bioactives, 14 antibiotics of diverse mechanism and chemical
class, to elucidate mechanism of action(s).
Combination Profiling Screen
This comparatively small number of priority actives (Figure 1)
generates a large number of possible experiments when com-
bined with 14 known bioctives, namely, 2604 pairwise combina-
tions. Indeed, chemical-chemical interaction studies to detect
synergy typically employ standard checkerboard methodology
using a 64-point dose matrix (Krogstad and Moellering, 1986).2–862, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 853
Figure 2. Chemical-Chemical Interaction Profiling Screen with
Known Bioactives
(A) Sample two-point dose matrix data showing three possible outcomes of
chemical-chemical interaction screens. The panels depict the effect of
combining a known bioactive compound with a priority active. Growth of the
combinations is represented by a black horizontal bar where the compound
concentrations are at one-quarter (1/4) and one-eighth (1/8) of their MICs as
indicated. Growth of the known bioactive compounds alone is described by
a white horizontal bar and that of the novel priority active alone is a gray bar.
All growth is comparedwith uninhibited controls and expressed as percentage
growth. (i) Example of an indifferent interaction, where the growth of the
combination of ampicillin andMAC-0002408 was not altered significantly rela-
tive to that obtained with the compounds individually. (ii) A highly synergistic
interaction is observed when norfloxacin and MAC-0003199 are combined
at one-quarter of their MICs. (iii) MAC-00038968 and sulfamethoxazole show
profound synergy at both at 1/4 and 1/8 of their MICs.
(B) Result of chemical-chemical interaction profiling of 2604 possible pairwise
combinations of 186 priority actives with 14 known antibiotics tested at one-
quarter (C) and one-eighth (B) MIC values to identify synergistic interactions.
Graphed are the average combination ratios (triplicate data) where percentage
Chemistry & Biology
Chemical-Chemical Interactions to Probe Mechanism
854 Chemistry & Biology 17, 852–862, August 27, 2010 ª2010 ElseviThus, a single replicate of the checkerboard methodology would
require more than 166,000 wells, excluding controls, to examine
our 186 priority actives in combination with 14 known bioactives
of diverse chemical class and antibacterial mechanism. Instead,
we developed a high-throughput method for the efficient identi-
fication of synergistic interactions, whereby two small molecules
at sublethal concentrations become growth inhibitory when
combined. We opted to combine compounds only at a quarter
and eighth of their MIC. This stems from the widely recognized
definition of synergy, as requiring a minimum of fourfold reduc-
tion in the MIC of both compounds in combination, compared
with each used alone (Krogstad and Moellering, 1986).
Combining bioactives at an eighth of their MICs allows for the
ready identification of highly synergistic interactions. Addition-
ally, since there is an inherent one-dilution variability when deter-
mining the MICs of the compounds alone (Rand et al., 1993),
combinations at an eighth of the MIC allow for a more conserva-
tive approach. This systematic two-point dose matrix allowed us
to test for synergistic interactions for all of the priority actives
when combined with the known bioactives in just 5200 wells.
In addition, all combinations were tested in triplicate, allowing
the assignment of a standard error to all percentage growth
values, and the inclusion of controls accounting for 20% of all
test wells ensured that all test samples could be normalized on
a plate by plate basis to cells to high controls. To check that
this high-throughput approach was as sensitive as the checker-
board method in detecting synergy, combination studies using
both methods were conducted on a random subset of 240 pairs
of small molecules and a 96% rate of agreement was calculated,
revealing the reliability of the two-point dose matrix in detecting
synergy (Figure S1).
Figure 2 highlights our two-point dose matrix approach
(Figure 2A) and shows average data from the combination
profiling screen of combinations at both 1/4 and 1/8 MIC
(Figure 2B). For this work, we defined the ‘‘combination ratio’’
as the ratio of the average percentage growth (from three repli-
cates) of cells exposed to the various combinations divided by
the average percentage growth in the presence of only the
known bioactives. Although the data were normalized to the
percentage growth in the presence of the known bioactive as
a single agent, the activity of each of the 186 priority actives
alone was also controlled for in the assay. In all cases, growth
in the presence of the priority actives as single agents resulted
in over 85% growth relative to the high control. A pair of com-
pounds with a combination ratio of 0.25 or lower was considered
synergistic. This represents a growth inhibition of at least 75%,
corresponding to the statistical threshold based on the high
controls in the screen (Zlitni et al., 2009). Figure 2A shows
detailed sample data from the two-point dose matrix approach,
where three possible chemical-chemical interaction scenarios
are depicted. Figure 2Ai shows an instance where thegrowth recorded for the compound combinations is normalized to the
percentage growth found for the known bioactives as single agents for all
186 test compounds. A statistical threshold of inhibition of 75% (normalized
ratio of 0.25) was established some three standard deviations away from the
mean of the high controls (DMSO). Compounds found below this line were
judged as hits.
See also Figure S1.
er Ltd All rights reserved
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no interactions. In Figure 2Aii, synergy is manifested at
one-quarter of the MIC for the two compounds but not at one-
eighth of the MIC, and in Figure 2Aiii, synergy is evident at
both one-quarter and one-eighth of the MIC. This analysis
allowed a straightforward assessment of the various chemical-
chemical interactions. Synergistic pairings were evident when
the effect on percentage growth was significantly reduced
when in combination, as compared with their effects individually.
These compounds were considered hits and further evaluated
in a full fingerprint of biological activity with the other known
bioactives.
Figure 2B shows average combination ratios for each of
the 186 priority actives with each of the 14 known bioactives.
For the most part, combinations led to only occasional synergy,
evident as a combination ratio of less than 0.25. Interestingly,
triclosan was found to be synergistic with a large number of
molecules, particularly at one-quarter MIC. This promiscuous
behavior is presumably due to the mechanism of triclosan, well
known as disruptor of bacterial membranes (Schweizer, 2001).
The next greatest preponderance of synergistic interactions of
the priority actives was with fosmidomycin, sulfamethoxazole,
and trimethoprim, where combination ratios were comparatively
low overall relative to the other known bioactives. We attribute
this trend to the shape of the dose-response curves for these
known bioactives which revealed a gradual inhibitory effect
compared with steeper dose-response curves for the other
known bioactive compounds (Figure S2A). The shallower dose-
response curve makes these compounds more prone to syner-
gistic interactions. At a concentration of one-quarter MIC, the
activity of the known bioactives would fall within the slope of
the dose-response curve such that it would be more inclined
to a drastic change in inhibitory activity upon combination with
a second agent. And while the combination ratios of fosmidomy-
cin, sulfamethoxazole, and trimethoprim are relatively low, the
effect of the combination is not strong enough to fall into our
statistically defined zone of synergy (<0.25). Indeed, we con-
firmed that this dose-response behavior leads to more frequent
synergy when using the standard 64-point dose matrix checker-
board analyses (Figure S2B).
Evaluation of Uncovered Synergistic Interactions
The combination profiling screen revealed that 45 of the 186
priority compounds had synergistic interactions with the 14
known bioactive compounds. At one-quarter MIC, a total of
112 compound combinations (excluding triclosan) were shown
to be capable of reducing the growth of E. coli MC1061 by at
least 75%. Triclosan showed an additional 143 synergistic
combinations. These results are presented in the form of
a heat map, where interactions of the priority actives with the
panel of known bioactives are colored based on the extent of
synergy measured (Figure 3). The heat map reveals a rich inter-
action matrix of the 45 synergistic priority actives with known
bioactives consistent with the thesis that chemical-chemical
interactions can uncover valuable functional connections for
uncharted small molecule inhibitors of bacterial growth.
When the known bioactives were combined with themselves,
very few combinations were synergistic. This was not unex-
pected, however, as these compounds were chosen to probeChemistry & Biology 17, 85diverse aspects of bacterial physiology. However, a small
number of known bioactives, fosmidomycin, sulfamethoxazole,
trimethoprim, and triclosan, were found to yield synergies.
Among these was trimethoprim and sulfamethoxazole, a signa-
ture interaction that has been long exploited in antibacterial
therapy (Rubin and Swartz, 1980). Additionally, fosmidomycin
was found to be synergistic with both trimethoprim and sulfame-
thoxale (Neu and Kamimura, 1982).
Having selected for priority actives that were synergistic with
known bioactives, the heat map details a high density of interac-
tions for these 45 molecules. Many of these are unique interac-
tions that reveal a fingerprint of selective biological activity. On
the other hand, many of the compounds demonstrated promis-
cuous synergistic interactions with several known antibiotics.
For example, MAC-0010522 was strongly synergistic with all
chosen known antibiotics. Such behavior suggested that this
compound might act on multiple pathways or affect cellular
permeability, perhaps enhancing the uptake of the known bioac-
tives. Thus, our screening approach had an ability to identify
nonselective molecules that would otherwise prove quite chal-
lenging in follow-up experiments to identify cellular target(s).
The promiscuous nature of these molecules can limit their utility
as chemical probes or as leads for drugs. Such molecules were
further assessed for their ability to permeabilize bacterial
membranes as described below.
Clustering of Chemical-Chemical Interaction Profiles
To assess whether there was a correlation of chemical-chemi-
cal interaction profiles and chemical structures, we performed
hierarchical clustering of the priority synergistic actives based
on their profiles (Figure 3) and on chemical similarity (Figure S3).
More than half the time, clustering by structural similarity
tracked with clustering by chemical-chemical interaction profile
(Figure S3). Examples of related compounds are shown in
Table 1. MAC-0007715 and MAC-0007720 share chemical
functionality, only differing in one of the thiourea side chains
possessing either a morpholine or 2-methylpiperdine ring, and
show a unique interaction fingerprint that includes erythro-
mycin, rifampicin, sulfamethoxazole, and triclosan. MAC-
0019671 and MAC-0020001 show a similar profile but with an
additional signature interaction with fosmidomycin, and only
differ in their substituents in the para position of the N-phenyl-
urea functionality. MAC-002303 and MAC-0024645 share a
1-(4-chlorophenyl)urea moiety and interacted uniquely with
fosmidomycin, sulfamethoxazole, and triclosan. These obser-
vations reinforce a well-established concept that chemical
structure dictates biological activity and reveal the predictive
power of our approach in assigning the potential chemical-
chemical interaction profile of a novel molecule. There are,
however, examples of molecules showing similar chemical-
chemical interactions when in combination, without being
structurally similar.
In this work, we were especially interested in following up on
compound combinations that showed unique synergies. Two
high interest compounds, MAC-0038968 and MAC-0003199,
were selected for follow-up experiments to characterize cellular
targets and mechanisms of action. We also investigated the
activity of a subset of priority actives that were found to be
promiscuously synergistic.2–862, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 855
Figure 3. Hierarchical Clustering of Chemical-Chemical Interaction
Profiles
Priority actives found to be synergistic with at least one known bioactive are
clustered according to their response when combined with the panel of known
antibiotics. Hierarchical cluster analysis was performed based on relative
Chemistry & Biology
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and Active against Dihydrofolate Reductase
One compound of interest uncovered in our screen was
MAC-0038968 (Figure 4A). This small molecule was found to
be uniquely synergistic with sulfamethoxazole, an antibiotic
that inhibits tetrahydrofolate biosynthesis in bacteria by acting
as an analog to one of the pathway intermediates (Walsh, 2003).
A detailed checkerboard analysis of the compound combination
confirmed strong synergy between MAC-0038968 with sulfame-
thoxazole with a fractional inhibitory index (SFIC) of 0.187
(Figure 4B). Interestingly, we previously reported on this com-
pound in a biochemical screen to identify inhibitors of dihydrofo-
late reductase (DHFR), the enzyme responsible for the reduction
of dihydrofolate to tetrahydrofolate but had not investigated its
cellular activity (Zolli-Juran et al., 2003). The observed synergy
served to validate the proposed method, as MAC-0038968,
which was found to be highly synergistic with sulfamethoxazole,
inhibits a later step in a common cellular pathway. To investigate
the cellular target of MAC-0038968, we sought to suppress the
action of this compound by expression of the putative target
DHFR at high copy. Indeed, we have previously found high
copy suppression to be a valuable chemical-genetic tool to
probe mechanism of novel antibacterial compounds (Li et al.,
2004; Pathania et al., 2009). Figure 4C reveals that increased
expression of DHFR led to a steady increase in the MIC for
MAC-0038968 and trimethoprim without any impact on the
MIC of the control compound tetracycline (Figure 4C). These
results are consistent with the conclusion that the growth
inhibition by MAC-0038968 was due to inhibition of DHFR.
Trimethoprim, one of the known bioactives in this study is of
course a celebrated DHFR inhibitor (Baccanari and Kuyper,
1993). The lack of synergy with trimethoprim (Figure 3A)
suggests that MAC-0038968 and trimethoprim bind to similar
sites on DHFR; otherwise a synergistic interaction would be ex-
pected if the two bound to separate sites on the target (Krogstad
andMoellering, 1986). In fact, we have previously shown that this
DHFR inhibitor, like trimethoprim, is competitive with the sub-
strate dihyrofolate and inhibits the enzyme with a reasonable
potency (Ki = 65 nM) (Zolli-Juran et al., 2003). Importantly
MAC-0038968 represents a new chemical class of DHFR inhib-
itors with cellular activity.
MAC-0003199 Is a DNA Gyrase Inhibitor,
Uncovered through Synergy with Norfloxacin
From the combinatorial screen the quinoline carboxylic acid,
MAC-0003199, was found to have a unique interaction finger-
print that included lincomycin, triclosan, and norfloxacin. The
latter interaction was particularly noteworthy as this compound
had a selective and profound interaction with this DNA gyrase
inhibitor. MAC-0003199 represents a novel structure but is
reminiscent of the quinolone family of synthetic antibiotics thatpercentage residual growth using Cluster software and displayed using
Treeview software (Eisen et al., 1998). Highly synergistic interactions are
represented in black. The asterisks (*) denote the two molecules of high
interest in this work: MAC-0038968, a dihydrofolate reductase inhibitor, and
MAC-0003199, a DNA gyrase inhibitor. The arrows to the right of the finger-
prints represent the molecules found to be membrane active as judged by
the DiSC3 fluorescence assay described herein.
See also Figures S2–S4.
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Biological fingerprints derived from the combination profiling screen with a panel of known antibiotics for the various molecules are shown,
where highly synergistic combinations are represented in black. The biological fingerprints were taken out of the heat map in Figure 3 to illustrate
the correlation between activity and chemical structures.
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and topoisomerase IV and associated lethal impact on DNA
replication and transcription.
A detailed checkerboard analysis of the interaction between
norfloxacin and MAC-0003199 confirmed the synergistic inter-Chemistry & Biology 17, 85action with a SFIC of 0.312 (Figure 5B). In an effort to assess
the capacity of MAC-0003199 to induce DNA damage, we char-
acterized the in vivo phenotypic response of E. coli in response
to the compound, employing a DNA damage-inducible reporter
construct that is based on LexA repression for regulation of2–862, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 857
Figure 4. MAC-0038968 Is Uniquely Syner-
gistic with Sulfamethoxazole and Active
against Dihydrofolate Reductase (DHFR)
(A) Chemical structure of MAC-0038968.
(B) Checkerboard analysis of MAC-0038968 in
combination with sulfamethoxazole, showing a
strong synergistic interaction with a SFIC = 0.187.
(C) Suppression of growth inhibition by MAC-
0038968 on increasing expression of DHFR
encoded in the folA gene. Here, expression is
manipulated by the arabinose-inducible promoter
of copy of pBAD18-folA in E. coli strain MC1061.
Arabinose dependence of the MIC is shown for
the positive control trimethoprim (circles, top
panel) and the test compound MAC-0038968
(circles, bottom panel). Also shown is the negative
control tetracycline (squares).
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cence is indicative of RecA-stimulated autocleavage of LexA
following recognition of DNA damage (Dwyer et al., 2007). The
control compound norfloxacin led to the induction of high levels
of fluorescence (Figure 5C). Norfloxacin is known to stabilize
a tripartite interaction with DNA gyrase and cleaved DNA thus
stimulating the formation of DNA breaks (Walsh, 2003). We
also observed a large shift in fluorescence upon treatment of
the cells with MAC-0003199 (Figure 5C), as compared with the
negative control, tetracycline (Figure 5C). We next sought to
determine whether MAC-0003199’s mode of action in the cell
was similar to that of norfloxacin, acting by inhibiting DNA
gyrase’s ability to supercoil DNA (Drlica and Zhao, 1997).
MAC-0003199 inhibited DNA gyrase at a relatively high concen-
tration, comparedwith the potent inhibitor norfloxacin (Figure 5D)
but nevertheless was consistent with the relative cellular
potencies of these compounds (6.4 mg/ml for MAC-0003199
compared with 0.025 mg/ml for norfloxacin).
Interestingly, the synergistic nature of the interaction
between MAC-0003199 and norfloxacin suggests that the two
molecules do not work with exactly the same mechanism. For
example, it seems unlikely that the two compounds bind to
exactly the same site on DNA gyrase as this would lead to an
antagonistic interaction (Krogstad and Moellering, 1986).
Further, MAC-0003199was found to be synergistic with triclosan
and lincomycin, while norfloxacin showed no such interaction.
Triclosan is known to disrupt the inner membrane of bacteria
(Schweizer, 2001), and this interaction may relate to inherent
permeability problems for MAC-0003199. Lincomycin is an
inhibitor of protein synthesis that binds the 50S ribosome and
inhibits peptidyl transferase activity, thus preventing translation
termination (Lin et al., 1997; Walsh, 2003). The mechanistic
connection between lincomycin and MAC-0003199 remains
unclear but suggests nevertheless that MAC-0003199 may not
function simply as an inhibitor of DNA gyrase. Its striking simi-858 Chemistry & Biology 17, 852–862, August 27, 2010 ª2010 Elsevier Ltd All rights reservedlarity in structure to the quinolone class
of molecules, however, strongly suggests
that MAC-0003199 is likely an inhibitor
of DNA gyrase, such that its interaction
with norfloxacin would expectedly be
antagonistic in nature. However, quino-lones have a unique mechanism of action in that they inhibit
both bacterial DNA gyrase and topoisomerase IV, with varying
target preference, depending on the organism in question. In
E. coli, the inhibition of topoisomerase IV becomes more
apparent when DNA gyrase is mutated to be resistant to the
quinolone (Khodursky et al., 1995). Moreover, quinolones can
in fact prefer topoisomerase IV over DNA gyrase, and vice versa,
or target both enzymes at nearly the same level (Takei et al.,
2001). This dual-targeting property of quinolones may help
explain the synergy between MAC-0003199 and norfloxacin, in
that the observed antibacterial activities are involved not only
in DNA gyrase inhibition but also in topoisomerase IV inhibition.
Promiscuously Synergistic Molecules
As discussed above, a particular advantage of systematic
screening for chemical-chemical interactions was the identifica-
tion of promiscuously synergistic molecules. In an effort to
understand the mode of action of such molecules, we investi-
gated the possibility that these were membrane active and
resulted in a breach in bacterial membrane potential. This was
assessed with a membrane potential-sensitive fluorescent
probe, 3,30-dipropylthiacarbocyanine (DiSC3) (Sims et al., 1974).
Once inside the cell, this dye becomes concentrated and
self-quenches its own fluorescence. Membrane-active com-
pounds that depolarize the Dc component of the proton motive
force will lead to the release of the dye and a consequent
increase in fluorescence. Normally, this dye is incapable of
penetrating Gram-negative bacteria; however, we were able to
establish this assay using our screening strain (E. coli strain
MC1061) because of its documented hyperpermeability. In
fact, we tested all compounds found to be synergistic in our
screen in our combination profiling screen for their capacity to
alter membrane potential at MIC concentrations. All 14 of the
known bioactives tested negatively in this assay, as expected,
whereas polymyxin B, a lipopeptide known to be membrane
Figure 5. MAC-0003199, Synergistic with
Norfloxacin, Inhibits DNA Gyrase
(A) Chemical structure of MAC-0003199.
(B) Checkerboard analysis of MAC-0003199 in
combination with norfloxacin, showing synergy
with a SFIC = 0.312.
(C) E. coli MC1061 harboring pL(lexO)-GFP, a
promoter-GFP reporter gene construct used to
report on DNA lesion formation, was grown to an
OD600of0.3–0.4and treatedwithvariousconcentra-
tion of norfloxacin (positive control), MAC-0003199
and tetracycline (negative control) (dashed line: no
drug; solid line: 1/4MIC; circles: 1/2MIC; diamonds:
MIC; squares: 23 MIC; triangles: 43 MIC). Optical
density at 600 nm and fluorescence at 535 nm
were monitored for 7 hr. Induction of DNA damage
was evident for norfloxacin and MAC-0003199.
(D) Inhibition of supercoiling of DNA by MAC-
0003199 and norfloxacin. E. coli gyrase was
incubated with relaxed pBR322 in the presence
of various concentrations of norfloxaxin (top
panel) and MAC-0003199 (bottom panel).The
lane labeled –G is relaxed pBR322 in the absence
of E. coli gyrase . R and S represent relaxed and
supercoiled pBR322, respectively.
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in DiSC3 fluorescence in our assay (Figure S4A). Of the 45
synergistic priority actives, 8 molecules caused a significant
increase in DiSC3 fluorescence, suggesting that thesemolecules
have the capacity to depolarize the cytoplasmic membrane.
These are highlighted with an arrow in Figure 3 to the right of their
respective chemical-chemical interaction profiles and the data
are presented in Figure S4B.
It is tempting to conclude that these eight molecules represent
nonselective compounds that are unsuitable probes of biology
or as leads for new drugs. Membrane-active molecules, such
as the peptide-drugs, daptomycin, and polymyxin B, have
proved invaluable in treating drug resistant infections (Evans
et al., 1999; Fuchs et al., 2002; Giamarellou and Poulakou,
2009; King and Phillips, 2001). Regardless of the disposition
toward membrane-active and promiscuous chemical matter,
the combination profiling approach used here was quiteChemistry & Biology 17, 852–862, August 27, 2010successful in identifying strong candi-
dates for membrane depolarizing activity
among priority actives.
DISCUSSION
The systematic determination of the
mechanism of actives derived from phe-
notype-based small molecule screening
remains a very significant challenge to
the discovery of useful probes of biology
or leads for new drugs. Chemical-genetic
approaches have dominated for this
purpose in recent years and, while the
success of these has been tangible, there
remain some significant drawbacks. For-
ward chemical-genetic methods rely onenhancement or suppression of growth phenotypes associated
with novel actives by genetic perturbation. The latter has the
potential to inform on mechanism and provide testable hypoth-
eses particularly when there is depth of knowledge on the inter-
actinggenes.Classical chemical-genetic approachesarepower-
ful but require the tedious isolation and characterization of
suppressing or enhancing mutants (Eggert et al., 2001; Gitai
et al., 2005; Heitman et al., 1991). Modern chemical-genomic
approaches have typically relied on genome-scale deletion or
overexpression clone-sets in model microbes such as yeast or
E. coli to screen for suppressing or enhancing genotypes (Baetz
et al., 2004; Giaever et al., 1999; Li et al., 2004; Lum et al., 2004b;
Pathania et al., 2009). Such clone sets are currently unavailable in
all but the most tractable model microbes.
Herein, we describe an alternative and complementary
approach where a small library of known bioactives is systemat-
ically combined with actives to detect chemical-chemicalª2010 Elsevier Ltd All rights reserved 859
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compounds were systematically combined with a library of
some 14 well-known antibiotics of diverse chemical class and
mechanism. Combination profiles so discovered were examined
in the context of a deep knowledge of themechanism of interact-
ing chemicals. These profiles generated hypotheses that were
testable with biochemical and physiological experiments and
revealed new probes of folate metabolism, DNA gyrase, and
the cell membrane. As such, chemical-chemical interaction pro-
files can be generated for any phenotype-inducing compound
in any biological systemwithout a need for geneticmanipulations
provided there are existing well-characterized chemical pertur-
bants available.
The work reported here suggests that phenotypic responses
to combinations of known and novel bioactives can reveal
information about thepathways and targets affectedby the latter.
The approachwas data rich but nevertheless allowed for efficient
testing of combinations of chemicals, making it readily adaptable
as a secondary screening approach in high-throughput
screening efforts. In a validating discovery, the bi-guanidine-con-
taining compound MAC-0038968 was found to be synergistic
with sulfamethoxazole. Sulfamethoxazole limits the supply of
PABA precursor available to subsequent steps in the tetrahydro-
folate biosynthesis pathway and iswell known for its synergywith
trimethoprim, an inhibitor of DHFR (Rubin and Swartz, 1980).
Further, we demonstrated that MAC-0038968, previously shown
to be a potent inhibitor of DHFR in vitro (Zolli-Juran et al., 2003),
could be suppressed by high copy DHFR, demonstrating that
his compound had cellular activity and was on target. Interest-
ingly, MAC-0038968 showed no synergy with trimethoprim,
presumably because these compounds bind to the same site
onDHFR.MAC-0003199, a quinoline carboxylic acid,was shown
to be aDNA-damaging agent that targetsDNAgyrase. Thismole-
cule, similar in structure to quinolones, was suitably found to be
highly synergistic with norfloxacin, a potent inhibitor of DNA
gyrase. The two novel inhibitors of bacterial physiology uncov-
ered through the use of chemical-chemical interactions highlight
the utility of the proposed approach in facilitating the search for
cellular targets of novel biological probes.
In cases where a novel compound shows promiscuous inter-
actions with multiple known bioactives, this nonselective
behavior can be used as a filter to eliminate nuisance com-
pounds. Other methods to identify such molecules include
computational means based on chemical functionality (Roche
et al., 2002; Walters et al., 1999). Another is a biochemical
approach that uses a detergent-based assay to counterscreen
for nonselective aggregating compounds (Feng et al., 2005;
McGovern et al., 2002; Seidler et al., 2003). There are, however,
few systematic counter screens for nonselective compounds
that are cell based. Interestingly, further study of such com-
pounds in the work reported here led to the discovery of a subset
of compounds capable of dissipating the transmembrane poten-
tial of E. coli. Given recent clinical success of the antibiotic dap-
tomycin, also know to depolarize membranes (Silverman et al.,
2003), promiscuous behavior might well be viewed as both
a strength and a weakness. Nevertheless, combination profiling
proved to be a powerful tool in identifying these molecules.
Interactions between bioactive chemicals can be synergistic
or antagonistic (Krogstad and Moellering, 1986). In this study,860 Chemistry & Biology 17, 852–862, August 27, 2010 ª2010 Elseviwe limited our focus to synergistic interactions. In the same
manner that synergies were specifically used to elucidate
mechanisms of action, a screen looking for antagonistic interac-
tions with known bioactives could also yield rich information
about associated cellular pathways. In brief, antagonistic inter-
actions aremost often observedwhen two compounds compete
between binding sites or when one alters the binding site of the
other (Krogstad and Moellering, 1986). Antagonism might also
be the result of complex genetic interactions propagated
through the cellular genetic network (D’Elia et al., 2009; Motter
et al., 2008). Thus, looking for antagonistic interactions among
novel and know bioactives, though rare, could surely also
provide useful mechanistic insights and testable hypotheses
regarding the mechanism of action of novel actives.
Herein we have demonstrated real promise for chemical-
chemical interactions in understanding mechanism of the
interacting components. So characterized, these interactions
also have the potential to perturb the complex and redundant
nature of biological pathways. It is increasingly becoming
evident that biological systems are composed of dense
networks of interacting components that are characterized by
redundancy (Ho et al., 2002; Tong et al., 2004). Thus, the simul-
taneous use of multiple perturbants will ultimately be required to
adequately describe this complex cellular matrix. As the
compendium of interacting combinations grows, these will
become an increasingly powerful tool for assessing mechanism
of action.SIGNIFICANCE
Phenotype-based screening provides a powerful tool for the
discovery and characterization of new probes of biology and
leads for new drugs; however, significant challenges remain
for connecting compounds to their targets. Here, we report
the application of systematic chemical-chemical combina-
tion profiling to understand the mechanism of action of anti-
bacterial compounds. The interaction of newly discovered
compounds with a panel of known bioactives of diverse
mechanism and chemical class was used to gain insight
into mode of action. Combination profiling for synergistic
chemical-chemical interactions resulted in a data-rich map
of interactions and led to testable hypotheses regarding
the mechanism of action of the bioactive molecules. One
such molecule was found to be an inhibitor of folate biosyn-
thesis, (MAC-0038968) and another was shown to be a DNA
gyrase inhibitor (MAC-0003199). The approach also proved
to be useful in identifying nonselective molecules that
showed promiscuous interaction behavior where a subset
of these compounds was shown to depolarize the bacterial
membrane.EXPERIMENTAL PROCEDURES
Bacterial Strains, Reagents, and General Methods
E. coli MC1061 was used for all experiments and follow-up work. Growth
media was liquid or agar Luria-Bertani Broth (LB). The small molecule library
was purchased from Maybridge (Cornwall, England) and was dissolved in
DMSO at a concentration of 6.4 mg/ml. All chemicals were purchased from
Sigma Aldrich (Oakville, ON).er Ltd All rights reserved
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Compounds using E. coli Strain MC1061
Theminimum inhibitory concentrationsof priority actives andknownantibiotics
were determined to characterize their growth inhibition. Typically, E. coli
MC1061 was grown overnight in 5 ml of LB media. The cells were then diluted
1:100 in fresh media and allowed to grow until the OD600 reached 0.4. The cells
were then diluted 1:100,000 and exposed to 2-fold serial dilutions of the
compounds at final concentrations ranging from 0 to 204.8 mg/ml from stock
solutionsof 6.4mg/ml. Thesewere tested in96-wellmicrowell plateswith a total
volume of 200 ml and incubated at 37C with 80% humidity for 18 hr before
determining optical density at 600 nm. The concentration where the optical
density was less than 0.05 was deemed the MIC of the test compound.
Combination Profiling Screen
To screen the various combinations, 80-fold stock solutions of chemicals were
placed into polypropylene 96-well master plates in two consecutive columns.
Aliquots of 2.5 ml from both master plates were dispensed into the assay plate
using a Biomek FX liquid handler (Beckman Coulter Inc., Fullerton, CA) in the
McMaster High Throughput Screening Laboratory. Subsequently, 195 ml of
a mid-log subculture of E. coli MC1061 cells diluted 1:100,000 were added.
These plates were incubated for 18 hr at 37C before being read for optical
density at 600 nm. All combinations were done in triplicate, allowing the
assignment of a standard error to all percentage growth values.
Checkerboard Analysis of Synergy
A mid-log subculture of E. coli MC1061 cells was diluted 1:100,000 before
adding to an 8 3 8 matrix of priority actives and known antibiotics. The plates
were incubated for 18 hr at 37C before reading for optical density at 600 nm.
All combinations were done in duplicate. Heat maps of the averages were
created in Excel and used to illustrate growth compared with the high controls
(DMSO only). To evaluate the effect of the combinations, the fractional inhibi-
tory concentrations (SFIC) indices were calculated. This metric is defined as
the sum of the MIC of each drug when used in combination divided by the
MIC when used alone. Chemical-chemical interactions with SFIC of less
than 0.5 were deemed synergistic.
High Copy Suppression of Growth Inhibition
E. coli MC1061 harboring pBAD18-folA was grown overnight in LB supple-
mented with 100 mg/ml ampicillin, subcultured the following day (1:100 dilution
in the samemedia) and grown to mid log (OD600 = 0.4) with aeration at 250 rpm
at 37C. The cells were then diluted 1:100,000 and exposed to 2-fold serial
dilutions of the compounds ranging from 0 to 102.4 mg/ml in the presence of
various concentration of arabinose (0%–3.2%). These were tested in 96-well
microwell plates (total volume of 200 ml) and incubated at 37C with 80%
humidity for 18 hr before determining optical density at 600 nm. The concen-
tration where the optical density was less than 0.05 was deemed the MIC.
Promoter-Reporter Construct Experiments
The DNA-damage reporter construct was a kind gift from Dr. James Collins
(Boston University). In all experiments, E. coli MC1061 harboring pL(lexO)-
GFP were grown overnight and then diluted 1:100 in 50 ml LB supplemented
with 100 mg/ml ampicillin. Cells were grown at 37C, 250 rpm, until an
OD600 of 0.3–0.4. Cells were aliquoted into black clear bottom 96-well plates
(Corning Life Sciences, Corning, NY) and drug, previously serially diluted
in stock plates, was added at various concentrations. Optical density at
600 nm and fluorescence at 535 nmwere monitored for 7 hr using the EnVision
from Perkin Elmer (Waltham, MA).
DNA Supercoiling Assay
E. coli gyrasewas incubatedwith 0.5 mg of relaxed pBR322DNA in a 30 ml reac-
tion mixture at 37C for 1 hr under the following conditions: 35 mM Tris-HCL
(pH 7.5), 24mMKCl, 4mMMgCl2, 2mMDTT, 1.75mMATP, 5mMspermidine,
0.1 mg/ml BSA, and 6.5% glycerol. Reactions were analyzed by electropho-
resis through a 0.8% agarose gel (run at 130V for 1.5 hr).
Dissipation of Transmembrane Potential
The transmembrane potential was determined with the fluorescent probe,
30-dipropylthiacarbocyanine (DiSC3(5)). E. coli MC1061 cells were washedChemistry & Biology 17, 85twice with Tris buffer (10 mM [pH 7.5]), and then resuspended to an optical
density at 600 nm of 0.35. DiSC3(5) was added at a final concentration of
0.4 mM, and the cells were incubated, with constant stirring to let the dye
stabilize. Compounds were then injected. Fluorescent traces were measured
in a fluorimeter (Photon Technology International) at the excitation and
emission wavelengths of 622 and 660 nm, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at doi:10.1016/j.chembiol.2010.06.008.
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